SLNO News

Are WSR, SLNO, OMEX, AVNS Obtaining Fair Deals for their Shareholders?

Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO

SLNO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 Ready to Announce with Confidence?

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Drug Safety Risks: SueWallSt

Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.’s Transaction with Neurocrine is Fair to Public Shareholders

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)

SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO

SLNO 13-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions – Hagens Berman